Histological and Physiological assessment of Endothelin-1 and Cholesterol in breast cancer of women

Authors

  • Hussein I. H. Al-Azzawi Department of Biology, College of Education for pure sciences, Tikrit university, Iraq
  • Zaid M. M. Almahdawi Department of Biology, College of Sciences, Tikrit university, Iraq
  • Ayad H. Ibrahim Department of Biology, College of Veterinary Medicine, Tikrit university, Iraq
  • Wieeam A. Saleh Department of Laboratory, Teaching Oncology Hospital - Medical City, Ministry of Health, Baghdad, Iraq

DOI:

https://doi.org/10.26452/ijrps.v13i2.94

Abstract

The current study included two aspects, one of which is histological and the other physiological. It included (75) blood samples from women with breast cancer, in addition to (15) blood samples for healthy women as control, in addition to collecting tissue biopsy from the mammary glands of some women whose blood samples were drawn Including them in advance. Those diagnosed with breast cancer and ages ranged between 38-68 years, where the study was conducted from 1 May 2019 to 2 October 2019. Gland tissue and the owner of those tumours swelling of the axillary lymph nodes. Another cancer that was found was papillary carcinoma, where epithelial hyperplasia appeared in the form of large papillae that filled the cavity of the gland. There is a large number of white blood cells and severe hematoma. Another type  of gland cancer discovered is cribriform carcinoma, which is a rare case. Invasive cancer is the most dangerous, as it is observed in the glandular tissue with the presence of agglutination and crowding of tumour cells and tumour cysts. The study also showed haematological changes characterized by a highly significant concentration of Endothelin-1 (P ≤ 0.01) in the blood of women with breast cancer group 5 and group 4, compared to the control group as a usual case. At the same time, there was a significant increase (P ≤ 0.05) in the con- centration of Endothelin-1 in infected women in groups 3, 2 and 6 compared to the control group. The study showed a very significant decrease (P ≤ 0.01) in the cholesterol concentration of women with breast cancer of group 5, and group 6 compared to the control group, while its level decreased significantly (P ≤ 0.05) in-group 4 compared to the control group. 

Keywords:

Breast Cancer, Endothelin-1, Cholesterol

Downloads

Download data is not yet available.

References

C H Takimoto and E Calvo. Principles of oncologic pharmacotherapy. Cancer Network home of the journal Oncology, pages 1–3, 2008.

D M Parkin. Cancer incidence in five continents. International Agency for Research on Cancer World Health Organization, 1997.

C I Li, J R Daling, and K E Malone. Age-specific incidence rates of in situ breast carcinomas by histologic type. Cancer Epidemiology Biomarkers and Prevention, 14(4):1008–1011, 2005.

L A G Ries, D Melbert, and M Krapcho. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Bethesda, MD, 2007.

Jack Sariego. Breast Cancer in the Young Patient. The American Surgeon, 76(12):1397– 1400, 2010.

S K Clinton, R L Beason, S Bryant, and J T Joh- son. Comparative study of four serological tumor markers for the detection of breast cancer. J. Bio. Med. Sci. Instrum, 39:408–414, 2003.

Rebecca L. Siegel, Kimberly D. Miller, and Ahmedin Jemal. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1):7–30, 2018.

A. M. Saaed, A. K. Sheikha, S. S. Mohammed, H. A. M. Ameen, S. Y. Sheet, and M. Khasraw. A survey of suspected familial breast cancer in Iraqi Kurdish women. Journal of Clinical Oncology, 29(15_suppl):1602–1602, 2011.

João Luis Garcia, Solange Maria Gennari, Rosângela Zacarias Machado, and Italmar Teodorico Navarro. Toxoplasma gondii: Detection by mouse bioassay, histopathology, and polymerase chain reaction in tissues from experimentally infected pigs. Experimental Parasitology, 113(4):267–271, 2006.

J D Bancroft and A A Stevens. Theory and practice of Histological Techniques. First Edition. pages 236–370, Edinburgh, London, 1996. Churehill Livingstone.

Anthony P. Davenport, Kelly A. Hyndman, Neeraj Dhaun, Christopher Southan, Donald E. Kohan, Jennifer S. Pollock, David M. Pollock, David J. Webb, and Janet J. Maguire. Endothelin. Pharmacological Reviews, 68(2):357–418, 2016.

Kaoqi Lian, Pingping Zhang, Wei Wang, Tingting Dai, and Lei Li. Determination of Total Cholesterol in Serum by Gas Chromatography Mass Spectrometry. Asian Journal of Chemistry, 26(9):2646–2648, 2014.

R C Duncan, R G Knap, and M C Miller. Introductory biostatistics for the health sciences, Modern Applications Including Bootstrap. pages 161–179, London, 2003. A Wiley Inter Science John Wiley and Sons.

W W Lam, A P Tang, G Tse, and W C Chu. Radiology-Pathology conference: Papillary carcinoma of the breast. Clin Imaging, 29(6):396–400, 2005.

A Dawson and D K Mulford. Benign versus malignant papillary neoplasms of the breast. Diagnostic clues in fine needle aspiration cytology. Acta Cytology, 38(1):23–28, 1994.

S. J. Bhosale, A. Y. Kshirsagar, S. R. Sulhyan, S. V. Jagtap, and Y. P. Nikam. Invasive Papillary Breast Carcinoma. Case Reports in Oncology, 3(3):410–415, 2010.

C W Elston. Classification and grading of invasive breast carcinoma. Verh Dtsch Ges Pathol, 89:35–44, 2005.

Y L Liu, C Choi, and S M Lee. Invasive lobular breast carcinoma: pleomorphic versus classical subtype, associations and prognosis. Clinical Breast Cancer, 18(2):114–120, 2018.

Shabnam Jaffer and Ira J. Bleiweiss. Histologic classification of ductal carcinoma in situ. Microscopy Research and Technique, 59(2):92–101, 2002.

D Tamkus, A Sikorskii, K A Gallo, D A Wiese, C Leece, B V Madhukar, S C Chivu, S Chit- neni, and N V Dimitrov. Endothelin-1 Enriched Tumor Phenotype Predicts Breast Cancer Recurrence. ISRN Oncology, 2013.

R M Kedzierski and M Yanagisawa. Endothelin system: the double-edged sword in health and disease. Annu Rev. Pharmacol Toxicol, 41:851– 876, 2001.

A. M. Malek, A. L. Greene, and S. Izumo. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proceedings of the National Academy of Sciences, 90(13):5999–6003, 1993.

Laura Rosanò, Francesca Spinella, and Anna Bagnato. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer, 13(9):637–651, 2013.

Matthew J. Grimshaw, Thorsten Hagemann, Ayse Ayhan, Cheryl E. Gillett, Claudia Binder, and Frances R. Balkwill. A Role for Endothelin- 2 and Its Receptors in Breast Tumor Cell Invasion. Cancer Research, 64(7):2461–2468, 2004.

Pia Wülfing, Raihanatou Diallo, Christian Ker- sting, Christian Wülfing, Christopher Poremba, Robert Greb, Werner Böcker, and Ludwig Kiesel. Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncology Reports, 11(4):791–796, 2004.

J. L. Wilson, J. Burchell, and M. J. Grimshaw. Endothelins Induce CCR7 Expression by Breast Tumor Cells via Endothelin Receptor A and Hypoxia-Inducible Factor-1, 2006.

S P Gampenrieder, C Hufnagl, S Brechel- macher, F Huemer, H Hackl, G Rinnerthaler, F Romeder, C Monzo Fuentes, P Morre, C Hauser-Kronberger, B Mlineritsch, and R Greil. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. The Pharmacogenomics Journal, 17(4):344–350, 2017.

Yesim Yildirim, Nazan Gunel, Ugur Coskun, Banu Sancak, Neslihan Bukan, Sabahattin Aslan, and Abdullah Cetin. Serum big endothelin-1 levels in female patients with breast cancer. International Immunopharmacology, 8(8):1119–1123, 2008.

V Kalles, I Papapanagiotou, M Matiatou, G Georgiou, C Theodoropoulos, T Triantafyl- lou, E Zografos, A Mitrousias, X Provatopoulou, and N V Michalopoulos. Evaluation of plasma and tissue expression levels of Endothelins (ET-1, Big ET-1) and VEGF in lobular neoplasia of the breast. JBUON, 24(5):1913–1919, 2019.

Anna Bagnato, Francesca Spinella, and Laura Rosanò. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin. Canadian Journal of Physiology and Pharmacology, 86(8):473–484, 2008.

Alanen, Deng, and Chakrabarti. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology, 36(2):161–167, 2000.

George Riley, Jennifer M. Lee, Mark Benson, Garth Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, Jennifer Hart, Douglas Hoffman, Jeffrey Hoover, Wonhee Jang, Kenneth Katz, Michael Ovetsky, Melissa J. Landrum, Amanjeev Sethi, Ray Tully, Ricardo Villamarin Salomon, Wendy Rubinstein, and Donna R. Maglott. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Research, 44(D1):D862–D868, 2016.

A K Haritwal, R K Chourasia, and S Ojha. A comparative study of serum lipid profile and glucose level between breast cancer patients and controls at tertiary care hospital in India. Inter J Medical Sci. Res Prac, 2(1):16–19, 2016.

Monika Sharma, Jo Tuaine, Blair McLaren, Debra L. Waters, Katherine Black, Lynnette M. Jones, and Sally P. A. McCormick. Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLOS ONE, 11(1):e0148049–e0148049, 2016.

Aseel N. Kamil, Basil O. Saleh, and Kifah H. Alani. Dyslipidemia and CA15-3 serum level in Iraqi Women with Breast Tumor: A Comparative Study. journal of the faculty of medicine Baghdad, 60(3):160–165, 2018.

Published

2022-04-05

How to Cite

Hussein I. H. Al-Azzawi, Zaid M. M. Almahdawi, Ayad H. Ibrahim, & Wieeam A. Saleh. (2022). Histological and Physiological assessment of Endothelin-1 and Cholesterol in breast cancer of women. International Journal of Research in Pharmaceutical Sciences, 13(2), 150–161. https://doi.org/10.26452/ijrps.v13i2.94

Issue

Section

Original Articles